Immunosuppressants are medicines that reduce the activity of the body’s immune system. They are used primarily in transplantation medicine to prevent the immune system from attacking and rejecting a donor organ such as a transplanted heart, and they are also used to treat certain autoimmune and inflammatory conditions in which the immune system mistakenly damages the body’s own tissues.
After heart transplantation, recipients must take immunosuppressant medicines for life. Without them, the immune system would recognise the donor heart as foreign and mount an attack (rejection) that could damage or destroy the organ. Common immunosuppressant regimens after cardiac transplantation combine calcineurin inhibitors (such as tacrolimus or ciclosporin), antiproliferative agents (such as mycophenolate mofetil), and corticosteroids. Doses are carefully titrated, and blood levels are monitored regularly.
The main risk associated with long-term immunosuppression is increased susceptibility to infections, including bacterial, viral, fungal, and opportunistic infections that a healthy immune system would normally control. Patients are also at higher risk of certain cancers over time, particularly skin cancers and lymphomas. Regular monitoring and specialist follow-up with the transplant team is essential to balance effective suppression against these risks.
In the context of inflammatory heart conditions such as myocarditis or endomyocarditis, immunosuppressants may be used in selected patients to reduce immune-driven damage to the heart muscle. In these cases, the aim is to limit ongoing inflammation rather than to prevent transplant rejection, and the choice of agent and duration of treatment are guided by the underlying cause and clinical response.
« Back to Glossary Index